Based on 17 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $97.81 with a high forecast of $110.00 and a low forecast of $83.00. The average price target represents a 39.81% change from the last price of $69.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Proxima_Nova_regular","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","78":"$78","89":"$89","100":"$100","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97.81,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$97.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,78,89,100,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Sep<br/>2023","25":"Sep<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.38,78.96615384615384,81.55230769230769,84.13846153846154,86.72461538461538,89.31076923076922,91.89692307692307,94.48307692307692,97.06923076923077,99.6553846153846,102.24153846153845,104.8276923076923,107.41384615384615,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.38,78.02846153846153,79.67692307692307,81.3253846153846,82.97384615384615,84.62230769230769,86.27076923076923,87.91923076923077,89.56769230769231,91.21615384615384,92.86461538461539,94.51307692307692,96.16153846153847,{"y":97.81,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,76.38,76.88923076923076,77.39846153846153,77.9076923076923,78.41692307692307,78.92615384615384,79.4353846153846,79.94461538461539,80.45384615384616,80.96307692307693,81.4723076923077,81.98153846153846,82.49076923076923,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.74,"date":1663891200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.23,"date":1665100800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.54,"date":1667520000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.55,"date":1669939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.01,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.12,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.92,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.88,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.74,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.34,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.26,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.55,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.38,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$97.81

Lowest Price Target$83.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

2023-09-26

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Upgraded

2023-09-26

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

2023-09-26

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Reiterated

2023-09-08

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Assigned

2023-08-17

xxxxxxxxxxxxxxxxxx

Credit Suisse

xxxxxxxxxxxxx

Reiterated

2023-08-02

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

2023-07-27

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

2023-07-27

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

2023-07-27

xxxxxxxxxxxxxxxxxx

Deutsche Bank

xxxxxxxxxxxxx

Reiterated

2023-07-27

William Plovanic

Canaccord Genuity

$89.00

Hold

27.22%

Upside

Reiterated

2023-07-27

Edwards Lifesciences price target lowered to $89 from $96 at CanaccordEdwards Lifesciences price target lowered to $89 from $96 at Canaccord

Vijay Kumar

Evercore ISI

$98.00

Buy

40.08%

Upside

Reiterated

2023-07-27

Edwards Lifesciences (EW) PT Lowered to $98 at Evercore ISIEvercore ISI analyst Vijay Kumar lowered the price target on Edwards Lifesciences (NYSE: EW) to $98.00 (from $100.00) while maintaining a Outperform rating.

Anthony Petrone

Mizuho Securities

$102.00

Buy

45.80%

Upside

Reiterated

2023-07-27

Mizuho Securities Keeps Their Buy Rating on Edwards Lifesciences (EW)

Patrick Wood

Morgan Stanley

$102.00

Buy

45.80%

Upside

Reiterated

2023-07-27

Richard Newitter

Truist Financial

$105.00

Buy

50.09%

Upside

Reiterated

2023-07-26

Best Analysts Covering Edwards Lifesciences

Which Analyst Should I Follow If I Want to Buy EW and Sell After:

1 Month

Suraj KaliaOppenheimer

Success Rate

16/27 ratings generated profit

Average Return

+1.75%

upgraded a buy rating 3 days ago

Copying Suraj Kalia's trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +1.75% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Matt MiksicBarclays

Success Rate

16/26 ratings generated profit

Average Return

+1.27%

reiterated a buy rating 2 months ago

Copying Matt Miksic's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +1.27% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Suraj KaliaOppenheimer

Success Rate

21/27 ratings generated profit

Average Return

+22.64%

upgraded a buy rating 3 days ago

Copying Suraj Kalia's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +22.64% per trade.

2 Years

Josh JenningsTD Cowen

Success Rate

24/30 ratings generated profit

Average Return

+37.37%

reiterated a buy rating 11 months ago

Copying Josh Jennings's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +37.37% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.59 with a range of $0.57 to $0.61. The previous quarter’s EPS was $0.66. EW beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.70% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.48B with a range of $1.45B to $1.52B. The previous quarter’s sales results were $1.53B. EW beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 44.66% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Analyst Recommendation Trends

In the current month, EW has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The EW average analyst price target in the past 3 months is $97.81

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is $97.81.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 39.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences has a conensus rating of Moderate Buy which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s price target?

The average price target for Edwards Lifesciences is $97.81. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $83.00. The average price target represents 39.81% Increase from the current price of $69.96.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Months Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Analyst Recommendation Trends

EW Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts